These scientists certainly deserve an A+ if the findings are accurate.
Moderna on Tuesday announced its COVID-19 vaccine is 100% effective in kids 12-17.
A perfect score should serve to put the minds of those seeking vaccinations for their children at ease, especially when the news was accompanied by this caveat: The clinical trials revealed that the vaccine showed “no significant safety concerns” in the process that included more than 3,700 adolescent participants, Moderna said.
As for the vaccine’s performance, Moderna said the results of the trials showed the vaccine was 93 percent effective two weeks after the first dose was administered and 100 percent effective after the second dose.
From here, Moderna will send the trial’s results to U.S. regulators.
“We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents. It is particularly exciting to see that the Moderna COVID-19 vaccine can prevent SARS-CoV-2 infection,” Moderna CEO Stéphane Bancel said in the announcement.
“We will submit these results to the U.S. FDA and regulators globally in early June and request authorization. We remain committed to doing our part to help end the COVID-19 pandemic.”
The U.S. Food and Drug Administration opened eligibility for the 12-17 age group by authorizing the Pfizer vaccine for those children in early May.
Pfizer said it would likely seek an emergency use authorization for its vaccine for children ages 2-11 in September.
An independent panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) then voted May 12 to recommend the Pfizer vaccine for use in children ages 12 to 15.
Moderna’s COVID-19 vaccine, along with the Johnson & Johnson vaccine, is already available for anyone 18 years and older in the U.S.